PH12021550621A1 - Ophthalmic compositions for treatment of ocular surface damage and symptoms of dryness - Google Patents
Ophthalmic compositions for treatment of ocular surface damage and symptoms of drynessInfo
- Publication number
- PH12021550621A1 PH12021550621A1 PH12021550621A PH12021550621A PH12021550621A1 PH 12021550621 A1 PH12021550621 A1 PH 12021550621A1 PH 12021550621 A PH12021550621 A PH 12021550621A PH 12021550621 A PH12021550621 A PH 12021550621A PH 12021550621 A1 PH12021550621 A1 PH 12021550621A1
- Authority
- PH
- Philippines
- Prior art keywords
- treatment
- dryness
- symptoms
- surface damage
- ocular surface
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- 208000024891 symptom Diseases 0.000 title abstract 2
- 210000004087 cornea Anatomy 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/02—Halogenated hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18196126 | 2018-09-22 | ||
| EP18198440 | 2018-10-03 | ||
| EP18202041 | 2018-10-23 | ||
| PCT/EP2019/075406 WO2020058504A1 (en) | 2018-09-22 | 2019-09-20 | Ophthalmic compositions for treatment of ocular surface damage and symptoms of dryness |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12021550621A1 true PH12021550621A1 (en) | 2022-02-14 |
Family
ID=68240699
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH12021550621A PH12021550621A1 (en) | 2018-09-22 | 2021-03-18 | Ophthalmic compositions for treatment of ocular surface damage and symptoms of dryness |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20210346313A1 (https=) |
| EP (1) | EP3852734A1 (https=) |
| JP (1) | JP2022500461A (https=) |
| KR (1) | KR20210080388A (https=) |
| CN (1) | CN112739335A (https=) |
| AU (2) | AU2019342426A1 (https=) |
| CA (1) | CA3111873A1 (https=) |
| IL (1) | IL281516A (https=) |
| PH (1) | PH12021550621A1 (https=) |
| SG (1) | SG11202102818YA (https=) |
| WO (1) | WO2020058504A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110403923B (zh) | 2015-09-30 | 2021-09-21 | 诺瓦利克有限责任公司 | 半氟化化合物和其组合物 |
| PT3442480T (pt) | 2016-06-23 | 2019-12-23 | Novaliq Gmbh | Método de administração tópica |
| CA3036297C (en) | 2016-09-22 | 2023-09-05 | Novaliq Gmbh | Pharmaceutical compositions for use in the therapy of blepharitis |
| WO2018055101A1 (en) | 2016-09-23 | 2018-03-29 | Novaliq Gmbh | Ophthalmic compositions comprising ciclosporin |
| EP4374851B1 (en) | 2016-12-23 | 2026-04-15 | Novaliq GmbH | Ophthalmic composition for treatment of dry eye disease |
| CA3058097C (en) | 2017-04-21 | 2024-01-02 | Novaliq Gmbh | Iodine compositions |
| MX2020003534A (es) | 2017-09-27 | 2020-07-29 | Novaliq Gmbh | Composiciones oftalmicas que comprenden latanoprost para usarse en el tratamiento de las enfermedades oculares. |
| WO2019068763A1 (en) | 2017-10-04 | 2019-04-11 | Novaliq Gmbh | OPHTHALMIC COMPOSITIONS COMPRISING F6H8 |
| KR20200128407A (ko) | 2018-03-02 | 2020-11-12 | 노바리크 게엠베하 | 네비볼롤을 포함하는 약제학적 조성물 |
| SG11202007860XA (en) | 2018-03-28 | 2020-09-29 | Novaliq Gmbh | Pharmaceutical composition comprising timolol |
| CN112153970A (zh) | 2018-04-27 | 2020-12-29 | 诺瓦利克有限责任公司 | 用于治疗青光眼的包含他氟前列素的眼用组合物 |
| EP3923907B1 (en) | 2019-02-13 | 2024-09-25 | Novaliq GmbH | Compositions and methods for the treatment of ocular neovascularization |
| KR20220058577A (ko) | 2019-09-06 | 2022-05-09 | 노바리크 게엠베하 | 포도막염 치료를 위한 안과용 조성물 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19938668B4 (de) | 1999-08-14 | 2006-01-26 | Bausch & Lomb Inc. | Tränenersatzmittel |
| EP1494681A4 (en) * | 2002-04-16 | 2008-08-06 | Collagenex Pharm Inc | PROCESS FOR THE SIMULTANEOUS TREATMENT OF OCULAR ROSACEA AND ACNE ROSACEA |
| EP2187900B1 (en) * | 2007-08-16 | 2016-11-09 | The Schepens Eye Research Institute, Inc. | Therapeutic compositions for treatment of inflammation of ocular and adnexal tissues |
| EP2335735A1 (en) | 2009-12-14 | 2011-06-22 | Novaliq GmbH | Pharmaceutical composition for treatment of dry eye syndrome |
| AU2013314303B2 (en) * | 2012-09-12 | 2018-01-18 | Novaliq Gmbh | Semifluorinated alkane compositions |
| CN113679699B (zh) * | 2012-09-12 | 2022-10-28 | 诺瓦利克有限责任公司 | 包含半氟化烷烃的混合物的组合物 |
| JP5982070B1 (ja) * | 2014-10-09 | 2016-08-31 | 株式会社メディプロデュース | まつ毛用洗浄剤 |
| CN110403923B (zh) * | 2015-09-30 | 2021-09-21 | 诺瓦利克有限责任公司 | 半氟化化合物和其组合物 |
| CA3036297C (en) * | 2016-09-22 | 2023-09-05 | Novaliq Gmbh | Pharmaceutical compositions for use in the therapy of blepharitis |
| WO2019068763A1 (en) * | 2017-10-04 | 2019-04-11 | Novaliq Gmbh | OPHTHALMIC COMPOSITIONS COMPRISING F6H8 |
-
2019
- 2019-09-20 WO PCT/EP2019/075406 patent/WO2020058504A1/en not_active Ceased
- 2019-09-20 CN CN201980062052.2A patent/CN112739335A/zh active Pending
- 2019-09-20 KR KR1020217011860A patent/KR20210080388A/ko active Pending
- 2019-09-20 JP JP2021514550A patent/JP2022500461A/ja active Pending
- 2019-09-20 CA CA3111873A patent/CA3111873A1/en active Pending
- 2019-09-20 AU AU2019342426A patent/AU2019342426A1/en not_active Abandoned
- 2019-09-20 SG SG11202102818YA patent/SG11202102818YA/en unknown
- 2019-09-20 EP EP19786907.6A patent/EP3852734A1/en active Pending
- 2019-09-20 US US17/278,585 patent/US20210346313A1/en active Pending
-
2021
- 2021-03-15 IL IL281516A patent/IL281516A/en unknown
- 2021-03-18 PH PH12021550621A patent/PH12021550621A1/en unknown
-
2025
- 2025-06-06 US US19/231,354 patent/US20250295607A1/en active Pending
- 2025-06-10 AU AU2025204313A patent/AU2025204313A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20210080388A (ko) | 2021-06-30 |
| SG11202102818YA (en) | 2021-04-29 |
| CN112739335A (zh) | 2021-04-30 |
| AU2025204313A1 (en) | 2025-06-26 |
| AU2019342426A1 (en) | 2021-05-20 |
| EP3852734A1 (en) | 2021-07-28 |
| US20250295607A1 (en) | 2025-09-25 |
| IL281516A (en) | 2021-04-29 |
| US20210346313A1 (en) | 2021-11-11 |
| WO2020058504A1 (en) | 2020-03-26 |
| CA3111873A1 (en) | 2020-03-26 |
| JP2022500461A (ja) | 2022-01-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12021550621A1 (en) | Ophthalmic compositions for treatment of ocular surface damage and symptoms of dryness | |
| PH12021550620A1 (en) | Ophthalmic composition for treatment of dry eye disease | |
| EP4445954A3 (en) | Cellular models of and therapies for ocular diseases | |
| MX2021004708A (es) | Metodos y composiciones para tratamiento de presbicia, midriasis y otros trastornos oculares. | |
| EP4248971A3 (en) | Compositions and methods of using nintedanib for treating ocular diseases with abnormal neovascularization | |
| EP4445870A3 (en) | Ophthalmic devices, system and methods that improve peripheral vision | |
| IL273531A (en) | Ophthalmic preparations containing latanoprost for use in the treatment of eye diseases | |
| MY186271A (en) | Ophthalmic compositions and methods of use therefor | |
| IL284344A (en) | Pharmaceutical preparations for the eyes and methods for the treatment of diseases of the surface of the eye | |
| MX2009012645A (es) | Formulaciones y metodos para tratar el ojo seco. | |
| MY196448A (en) | Anti-Htra1 Antibodies and Methods of use Thereof | |
| EA202092748A1 (ru) | Модуляторы экспрессии apol1 | |
| EP4286013A3 (en) | Lrrc33 inhibitors and use thereof | |
| MX387804B (es) | Metodos para tratar presion intraocular con activadores de tie-2 | |
| MX393900B (es) | Uso de gaboxadol en el tratamiento de tinnitus. | |
| NZ746468A (en) | Methods of treating ocular conditions | |
| MX2020012011A (es) | Conjugados y derivados de prostaglandina para tratar el glaucoma y la hipertension ocular. | |
| PH12021550122A1 (en) | Solubilized apyrases, methods and use | |
| EA202091655A1 (ru) | Композиции и способы лечения нарушений сетчатки | |
| EP3691654A4 (en) | OPHTHALMIC PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATMENT OF EYE SURFACE DISEASES | |
| WO2017129577A8 (en) | Ophthalmic gabapentin for the treatment of corneal ulcers | |
| MX2025015454A (es) | Formulaciones/composiciones que comprenden ibrutinib | |
| EP4371613A3 (en) | Compounds for use in the treatment of ocular pain | |
| TW201613596A (en) | Ophthalmic suspension preparation | |
| NZ734845A (en) | Use of short synthetic peptide for the treatment and/or prophylaxis of dry eye disease |